GSK secures option to multiple high-value, validated Alzheimer’s-relevant targets for drug discovery, development, and commercialization
CMG1A46 is an investigational T cell-engager with potential to deeply deplete uncontrolled B cells present in autoimmune diseases such as lupus
New Chair brings extensive experience in global pharmaceutical and biotechnology leadership, healthcare innovation, and strategic drug development
GSK and Flagship to jointly fund up to $150 million upfront
Decision on EU marketing authorisation for this population expected by September 2024
CureVac receives €400 million upfront and up to an additional €1.05 billion in development, regulatory and sales milestone payments as well as tiered royalties; all previous financial considerations from the prior collaboration agreement replaced
Over 13 million US adults aged 50-59 years have a medical condition that increases their risk of severe RSV outcomes
Oligonucleotides are a unique modality with potential to address hard-to-treat diseases with high unmet need
Scientific consensus is that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer and GSK will continue to vigorously defend itself against all claims
The award recognizes powerful science–industry collaborations for social good
Subscribe To Our Newsletter & Stay Updated
